RE:RE:RE:RE:RE:RE:RE:ONCY to make an "Oral Presentation" on Bracelet-1 at ASCOWhy would you say that they would make a move now when Pfizer & Merck KGaA have already seen the results and I would assume with an NDA so has Roche. what's different now?
Moonshot,
I have wondered the same thing. One point that has been made is that the survival data seems to be important in terms of the amount of an offer. That has at least been implied strongly in the last big presentation by ONCY about when they would respond to an offer.